NASDAQ:PIRSPieris Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Pieris Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.24 +0.08 (+2.53 %) (As of 08/13/2020 04:00 PM ET) Add Compare Share Today's Range$3.13Now: $3.24▼$3.4550-Day Range$2.57MA: $2.98▼$3.3252-Week Range$1.60Now: $3.24▼$5.97Volume1.48 million shsAverage Volume493,181 shsMarket Capitalization$169.77 millionP/E RatioN/ADividend YieldN/ABeta1.37 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. Its lead respiratory program includes PRS-060, a drug candidate, which is in Phase I clinical trial that binds to IL-4Ra for the treatment of asthma and other inflammatory diseases; and lead immuno-oncology program comprises PRS-343, a bispecific protein that is in Phase I clinical trial for oncology diseases. The company is also developing PRS-344, a bispecific anticalin-antibody fusion protein that is in preclinical stage for oncology diseases; and PRS-080, a polyethylene glycol conjugated anticalin protein that is in Phase IIa clinical trial to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis, as well as other drugs. It has strategic partnerships with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seattle Genetics Inc., as well as others; and non-strategic license or option agreements with Aska Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc., and Sanofi, as well as license agreements with TUM, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingPieris Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.00, Pieris Pharmaceuticals has a potential upside of 116.0% from its current price of $3.24.Amount of Analyst CoveragePieris Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesPieris Pharmaceuticals has received 270 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPieris Pharmaceuticals has received 247 “underperform” votes. (Add your “underperform” vote.)Community SentimentPieris Pharmaceuticals has received 52.22% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Pieris Pharmaceuticals and other stocks. Vote “Outperform” if you believe PIRS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PIRS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPieris Pharmaceuticals does not currently pay a dividend.Dividend GrowthPieris Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pieris Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,605,000.00 in company stock.Percentage Held by InsidersOnly 5.74% of the stock of Pieris Pharmaceuticals is held by insiders.Percentage Held by Institutions70.22% of the stock of Pieris Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Pieris Pharmaceuticals are expected to decrease in the coming year, from ($0.65) to ($0.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pieris Pharmaceuticals is -6.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pieris Pharmaceuticals is -6.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPieris Pharmaceuticals has a P/B Ratio of 3.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.42 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PIRS Previous Symbol CUSIPN/A CIK1583648 Webwww.pieris.com Phone857-246-8998Debt Debt-to-Equity RatioN/A Current Ratio4.80 Quick Ratio4.80Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$46.28 million Price / Sales3.67 Cash FlowN/A Price / Cash FlowN/A Book Value$0.93 per share Price / Book3.48Profitability EPS (Most Recent Fiscal Year)($0.56) Net Income$-25,470,000.00 Net Margins-42.26% Return on Equity-61.01% Return on Assets-16.82%Miscellaneous Employees107 Outstanding Shares52,399,000Market Cap$169.77 million Next Earnings Date11/9/2020 (Estimated) OptionableOptionable $3.24 +0.08 (+2.53 %) (As of 08/13/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive PIRS News and Ratings via Email Sign-up to receive the latest news and ratings for PIRS and its competitors with MarketBeat's FREE daily newsletter. Pieris Pharmaceuticals (NASDAQ:PIRS) Frequently Asked Questions How has Pieris Pharmaceuticals' stock price been impacted by Coronavirus? Pieris Pharmaceuticals' stock was trading at $2.23 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PIRS stock has increased by 45.3% and is now trading at $3.24. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Pieris Pharmaceuticals? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pieris Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Pieris Pharmaceuticals. When is Pieris Pharmaceuticals' next earnings date? Pieris Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, November 9th 2020. View our earnings forecast for Pieris Pharmaceuticals. How were Pieris Pharmaceuticals' earnings last quarter? Pieris Pharmaceuticals Inc (NASDAQ:PIRS) announced its quarterly earnings results on Monday, August, 10th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.17) by $0.08. Pieris Pharmaceuticals had a negative return on equity of 61.01% and a negative net margin of 42.26%. View Pieris Pharmaceuticals' earnings history. What price target have analysts set for PIRS? 3 Wall Street analysts have issued 12 month target prices for Pieris Pharmaceuticals' stock. Their forecasts range from $5.00 to $9.00. On average, they expect Pieris Pharmaceuticals' stock price to reach $7.00 in the next year. This suggests a possible upside of 116.0% from the stock's current price. View analysts' price targets for Pieris Pharmaceuticals. Has Pieris Pharmaceuticals been receiving favorable news coverage? News coverage about PIRS stock has trended negative on Friday, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Pieris Pharmaceuticals earned a daily sentiment score of -2.4 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news about Pieris Pharmaceuticals. Are investors shorting Pieris Pharmaceuticals? Pieris Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 1,760,000 shares, an increase of 25.2% from the March 15th total of 1,405,300 shares. Based on an average daily trading volume, of 551,700 shares, the days-to-cover ratio is presently 3.2 days. View Pieris Pharmaceuticals' Short Interest. Who are some of Pieris Pharmaceuticals' key competitors? Some companies that are related to Pieris Pharmaceuticals include STARPHARMA HOLD/S (SPHRY), Anavex Life Sciences (AVXL), Luna Innovations (LUNA), Eloxx Pharmaceuticals (ELOX), Auxly Cannabis Group (CBWTF), BIOQUAL (BIOQ), Bioanalytical Systems (BASI), AIkido Pharma (AIKI), Cleveland BioLabs (CBLI), HedgePath Pharmaceuticals (HPPI), Tenax Therapeutics (TENX), Geovax Labs (GOVX), Vitality Biopharma (VBIO), US Stem Cell (USRM) and Protalex (PRTX). View all competitors. What other stocks do shareholders of Pieris Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pieris Pharmaceuticals investors own include Verastem (VSTM), Corbus Pharmaceuticals (CRBP), TG Therapeutics (TGTX), Sorrento Therapeutics (SRNE), Allena Pharmaceuticals (ALNA), Dynavax Technologies (DVAX), Sangamo Therapeutics (SGMO), Viking Therapeutics (VKTX), Amarin (AMRN) and Nektar Therapeutics (NKTR). Who are Pieris Pharmaceuticals' key executives? Pieris Pharmaceuticals' management team includes the following people: Mr. Stephen S. Yoder, CEO, Pres & Director (Age 43)Dr. Allan Reine, Sr. VP, CFO & Treasurer (Age 44)Dr. Louis A. Matis, Sr. VP & Chief Devel. Officer (Age 68)Mr. Claus Schalper MBA, Co-Founder & Sr. AdvisorMaria Kelman, Director of Investor Relations What is Pieris Pharmaceuticals' stock symbol? Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS." Who are Pieris Pharmaceuticals' major shareholders? Pieris Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Candriam Luxembourg S.C.A. (4.48%), Platinum Investment Management Ltd. (0.97%), Assenagon Asset Management S.A. (0.97%), Goldman Sachs Group Inc. (0.68%), Clear Harbor Asset Management LLC (0.39%) and Sigma Planning Corp (0.35%). Company insiders that own Pieris Pharmaceuticals stock include Aquilo Capital Management, Llc, Bvf Partners L P/Il and Christopher P Kiritsy. View institutional ownership trends for Pieris Pharmaceuticals. Which major investors are selling Pieris Pharmaceuticals stock? PIRS stock was sold by a variety of institutional investors in the last quarter, including Creative Planning, Clear Harbor Asset Management LLC, and UBS Group AG. Company insiders that have sold Pieris Pharmaceuticals company stock in the last year include Aquilo Capital Management, Llc, and Bvf Partners L P/Il. View insider buying and selling activity for Pieris Pharmaceuticals. Which major investors are buying Pieris Pharmaceuticals stock? PIRS stock was bought by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Assenagon Asset Management S.A., Platinum Investment Management Ltd., Sigma Planning Corp, California Public Employees Retirement System, Prudential Financial Inc., Athanor Capital LP, and Goldman Sachs Group Inc.. View insider buying and selling activity for Pieris Pharmaceuticals. How do I buy shares of Pieris Pharmaceuticals? Shares of PIRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Pieris Pharmaceuticals' stock price today? One share of PIRS stock can currently be purchased for approximately $3.24. How big of a company is Pieris Pharmaceuticals? Pieris Pharmaceuticals has a market capitalization of $169.77 million and generates $46.28 million in revenue each year. The biotechnology company earns $-25,470,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Pieris Pharmaceuticals employs 107 workers across the globe. What is Pieris Pharmaceuticals' official website? The official website for Pieris Pharmaceuticals is www.pieris.com. How can I contact Pieris Pharmaceuticals? Pieris Pharmaceuticals' mailing address is 255 State Street 9th Floor, Boston MA, 02109. The biotechnology company can be reached via phone at 857-246-8998 or via email at [email protected] This page was last updated on 8/14/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
